Gupta Tarana, Aggarwal Hari K, Goyal Sandeep, Singh Virendra
Department of Medicine, Post Graduate Institute of Medical Sciences, Pandit Bhagwat Dayal Sharma University of Health Sciences, Rohtak, Haryana, India.
Himachal Pradesh, India.
Euroasian J Hepatogastroenterol. 2020 Jan-Jun;10(1):7-10. doi: 10.5005/jp-journals-10018-1311.
Genotype 3 increases fibrosis in chronic hepatitis C (CHC).
To evaluate the effect of the hepatitis C virus (HCV) genotype on prevalence and severity of liver disease in CHC.
Nine hundred and forty-nine individuals with positive anti-HCV from June 2016 to May 2017 were enrolled in the study. We compared biochemical and hematological parameters, HCV RNA load, transient elastography, and ultrasound, in genotype 3 and nongenotype 3 patients. Cirrhosis was diagnosed in patients with liver stiffness measurement (LSM) ≥13 kPa.
Out of 835 CHC patients, overall, genotype 3 had higher LSM (11.3 vs 7.62, = 0.01), higher aspartate aminotransferase (AST) (88.4 vs 68.6, = 0.02), and low platelets (228.4 vs 261, = 0.03) with higher prevalence of cirrhosis (115/415 vs 25/245, = 0.01) than nongenotype 3. However, decompensation rates were not significantly different between two groups (32/115 vs 7/25, = 0.98). The subgroup analysis revealed that cirrhotic genotype 3 had advanced age (50 vs 35, < 0.01), male predominance, and higher AST (74.4 vs 57, = 0.01) as compared to noncirrhotic genotype 3 patients. On multivariate analysis, age and AST values were higher in cirrhotic than noncirrhotic genotype 3 patients.
Genotype 3 patients have higher prevalence of cirrhosis and fibrosis compared to nongenotype 3 patients; however, decompensation was not different between two groups.
Gupta T, Aggarwal HK, Goyal S, Prediction of Cirrhosis in Patients with Chronic Hepatitis C by Genotype 3. Euroasian J Hepato-Gastroenterol 2020;10(1):7-10.
3型基因型会增加慢性丙型肝炎（CHC）的纤维化程度。
评估丙型肝炎病毒（HCV）基因型对CHC患者肝病患病率和严重程度的影响。
纳入2016年6月至2017年5月抗-HCV阳性的949例个体。我们比较了3型基因型和非3型基因型患者的生化和血液学参数、HCV RNA载量、瞬时弹性成像和超声检查结果。肝硬度测量（LSM）≥13 kPa的患者被诊断为肝硬化。
在835例CHC患者中，总体而言，3型基因型患者的LSM更高（11.3对7.62，P = 0.01），天冬氨酸转氨酶（AST）更高（88.4对68.6，P = 0.02），血小板更低（228.4对261，P = 0.03），肝硬化患病率更高（115/415对25/245，P = 0.01）。然而，两组的失代偿率无显著差异（32/115对7/25，P = 0.98）。亚组分析显示，与非肝硬化的3型基因型患者相比，肝硬化的3型基因型患者年龄更大（50对35，P < 0.01），以男性为主，AST更高（74.4对57，P = 0.01）。多因素分析显示，肝硬化的3型基因型患者的年龄和AST值高于非肝硬化患者。
与非3型基因型患者相比，3型基因型患者的肝硬化和纤维化患病率更高；然而，两组的失代偿情况没有差异。
Gupta T, Aggarwal HK, Goyal S, 3型基因型对慢性丙型肝炎患者肝硬化的预测作用。《欧亚肝脏胃肠病学杂志》2020；10(1):7 - 10。
